Publications: Dr Helen Le Dieu
Rezvani K, Kanfer EJ, Marin D, Gabriel I, Rahemtulla A, Taylor A, Macdonald D, Dazzi F et al.(2012).
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Biol Blood Marrow Transplant
vol. 18,
(2)
235-240.
O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosen L et al.(2009).
Array-based DNA methylation profiling in follicular lymphoma. Leukemia
vol. 23,
(10)
1858-1866.
Le Dieu R, Taussig D, Ramsay AG, Mitter R, Lee AM, Lister TA, Gribben JG(2009).
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood
vol. 114,
(18)
3909-3916.
Le Dieu R, Taussig D, Lister TA, Gribben JG(2009).
Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. Journal of Immunological Methods
vol. 348,
(1-2)
95-100.
Gorgun G, Ramsay AG, Holderried TAW, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce C et al.(2009).
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. PNAS
vol. 106,
(15)
6250-6255.
Le Dieu R, Ramsay AG, Taussig D, Mitter R, Gribben JG (2008).
Differential Gene Expression Profile Identifies the Nature of T Cell Defects in AML Patients at Diagnosis. Blood.
vol. 112,
1186-1186.
Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG(2008).
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest
vol. 118,
(7)
2427-2437.
Le Dieu R, Gribben JG(2008).
Chronic Lymphocytic Leukaemia. Hematopoietic Stem Cell Transplantation,
Editors: Soiffer, RJ,
Edition. 1,
Springer
Le Dieu R, Taussig D, MacDougal F, Lister A, Gribben JG (2007).
CD3+/CD56+cells, but not natural killer T cells, are increased in peripheral blood of untreated patients with leukemia. BLOOD.
vol. 110,
538A-538A.
Le Dieu R, Gribben JG(2007).
Transplantation in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports
vol. 2,
(1)
56-61.
Sekhar M, Narat S, Le Dieu R, Luqmani A, Hollamby S, Alobaidi M, Hughes G (2006).
Major obstetric haemorrhage in late termination of pregnancy in eight women. BLOOD.
vol. 108,
89B-90B.
Le Dieu R, Gribben J(2006).
Vaccine- and immune-based therapy in chronic lymphocytic leukemia. SEMIN ONCOL
vol. 33,
(2)
220-229.
Le Dieu R, Gribben JG(2006).
Allogeneic Stem Cell Transplantation for Non-Hodgkin's and Hodgkin's Lymphoma. The lymphomas,
Editors: Canellos, GP, Lister, TA, Young, BD,
Edition. 2,
W B Saunders Co
Le Dieu R, Gribben J(2005).
CD40 activation: lessons for HIV immunotherapy from malignancies?. J HIV Ther
vol. 10,
(3)
51-55.
Ledieu R, Gorgun G, Gribben J (2005).
In vivo demonstration of donor idiotype specific T cells that kill primary CLL cells post allogeneic transplant.
Conference: ASH
from: 11/2005
Le Dieu R, Bua M, Andreasson C, Olavarria E, Goldman JM, Apperley JF, Maria D (2004).
Homoharringtonine in combination with imatinib for patients with CML who have achieved partial or complete cytogenetic responses. BLOOD.
vol. 104,
289A-289A.
Le Dieu R, Luckit J, Sundarasun M(2003).
Complications of trephine biopsy. Br J Haematol
vol. 121,
(6)
Smith J, Goldsmith C, Ward A, LeDieu R(2000).
IGF-II ameliorates the dystrophic phenotype and coordinately down-regulates programmed cell death. Cell Death and Differentiation
vol. 7,
(11)
1109-1118.
